https://doi.org/10.31288/oftalmolzh201353440

Using statins and fibrates for stabilization of diabetic retinopathy progression in patients with diabetes type 2

Bezdetko PA, Ajaj SM, Ilyina YN

Kharkiv National Medical University        

Purpose. The expansion of drug therapy for diabetic retinopathy by the addition of statins and fibrates (as correctors dyslipidemia) to stabilize its progression in patients with type 2 diabetes with glycated hemoglobin decompensation.

Material and methods. 74patients with type 2 diabetes and nonproliferative diabetic retinopathy were observed within one year. Visometry, tonometry, biomicroscopy, gonioscopy, ophthalmoskopy, perimetry, fluorescein angiography, optical coherence tomography, electrophysiological studies were done.

Results. Level of glycosylated hemoglobin was decompensated (up 7.5 %) and there was mixed dyslipidemia in all cases. Control patients received drug treatment with using antioxidants and angioprotektors, a study group additionally had been prescribed statins and fibrates. This treatment allowed to decrease a level of lipids up to 50 %, level of MD, quantity of local defects, macula volume by 10 %, average thickness of the central retina by 15 % and stabilize еру progression of nonproliferative diabetic retinopathy 1.5 times within one year.

Key words: nonproliferative diabetic retinopathy, glycosylated hemoglobin, dyslipidemia, statins, fibrates.  

References

1. Balabolkin MI, Klebanova EM, Kremnevskaya VM. Patho¬genesis of angiopathy in diabet. Sakharnyi diabet. 2009; 1: 99- 107.

2. Balabolkin MI. Diabetes mellitus. Moscow: Meditsina; 2004. 173 p.

3. Volkova EG. Guidance on correction of lipid disorders and atherosclerosis in diabetic patients. Chelyabinsk: Ural Med Academy of Post graduate Education; 2005. 136 p.

4. Gatsko GG, Zhukova AS, Pozdnyakova EA. Age-related peculiarities of effect of insulin on lipolysis and lipid per-oxidation in the adipose tissue of rats. Problemy endokri-nologii. 2003; 29(4): 86- 9.

5. Genes VS, Genes SG. Etiology, pathogenesis and pathoge-netic approach to therapy of NIDDM. Pat. fis. i eksperim.

ter. 2003; 4: 54-8.

6. Dedov II, Aleksandrov AA. Problems and prospects of lipid-lowering therapy for patients with diabetes. Sakharnyi diabet. 2000; 2(7): 9-12.

7. Dedov II, Shestakova MV. Diabetes mellitus. M.: Medizdat; 2009. (Guidance for doctors)

8. Dedov II, Shestakova MV, Maksimova MA. Federal Terget programme diabetes mellitus. Moscow; 2002. 59 p.

9. Milenkaya TM, Bessmertnaya EG, Aleksandrova VK et al. Diabetic retinopathy and antioxidants. Sakharnyi diabet. 2003; 2: 30-4.

10. Yermakova NA, Antsiferov MB, Klimova NV. Clinical value of early indicating diabetic retinopathy. M.: Medizdat; 2006. 47 p.

11. Yefimov AS, Skrobonskaya NA. Clinic diabetology. 1st edition. K.: Zdorovie; 1998. 320 p.

12. Kriteria of compensation of carbohydrate metabolism dis-orders and target values of HbA1C in diabetes mellitus: the federal program «Diabetes» [method. recommendations for doctors.. Grandfathers I, editor. M.: Medizdat; 2007. 37 p.

13. Lopach SN, Chubenko AV, Babich PN. Statistic methods in biomedical researches using Escel. K.: Morion; 2000. 320 p.

14. Ponomarchuk VS, Slobodyanik SB, Drozhenko VS. Ap-plication of phosphene electrostimulation in treatment of patients with partial atrophy of the optic nerve and am-blyopia [method. recommendations]. Odessa: astroprint; 1999. 14 p.

15. Smirnova OM. First identified type 2 diabetes. Diagnosis, treatment strategy. Guidance. M.; 2008.

16. Glantz. Biomedical statistics. Danilova, translator. Moscow: Praktika; 1999.

17. Diabetes Care. American Diabetes Association. Suppl. 1, 2008. 143 p.

18. Howard BV. Pathogenesis of diabetic dyslipidaemia. Diabetes Rev. 2005; 3: 423- 2.

19. Parish S, Offer A, Clarke R et al. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet; 2009; 360: 7-22.
Crossref

20. Aiello L, Beetham W, Marios CB et al. Ruby laser photo-coagulation in treatment of proliferative diabetic retinopathy. Goldberg M, editor. Washington DC.: USDHEW Pub. N.1890; 1968. 437-63.

21.Steiner G. Effect of fenofibrate on progression of coro¬nary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet; 2010; 375: 905-10.

22.WHO/IDF Europe. Diabetes Care and Research in Eu¬rope. Diabetic Medicine. The St. Vinsent Declaration, 1990; 7. 360 p.
Crossref